Fitusiran: The first approved siRNA therapy for hemophilia via reducing plasma antithrombin levels
{{output}}
Hemophilia is a coagulation disorder caused by deficiencies in clotting factors and is primarily classified into hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency). Current treatment relies predominantly on replacement therapy, where... ...
